Rituximab Therapy for Refractory Orbital Inflammation Results of a Phase 1/2, Dose-Ranging, Randomized Clinical Trial
Eric B Suhler, Lyndell L Lim, Robert M Beardsley, Tracy R Giles, Sirichai Pasadhilka, Shelly T Lee, Alexandre de Saint Sardos, Nicholas J Butler, Justine R Smith, James T Rosenbaum
JAMA Ophthalmology | AMER MEDICAL ASSOC | Published : 2014
Study expenses and drug were provided by Genentech, San Francisco, California. Additional research support was provided by the Department of Veterans' Affairs (Dr Suhler), Research to Prevent Blindness (unrestricted grant to Casey Eye Institute, Senior Scholar Award to Dr Rosenbaum), the Rosenfeld Family Trust (Dr Rosenbaum), and the William and Mary Bauman Foundation.